Document is current
Any future updates will be listed below
-
Authors
Savarirayan, Ravi http://orcid.org/0000-0002-5105-8427
Ireland, Penny
Irving, Melita
Thompson, Dominic
Alves, Inês http://orcid.org/0000-0001-8963-4736
Baratela, Wagner A. R.
Betts, James
Bober, Michael B.
Boero, Silvio
Briddell, Jenna http://orcid.org/0000-0001-9104-2190
Campbell, Jeffrey
Campeau, Philippe M. http://orcid.org/0000-0001-9713-7107
Carl-Innig, Patricia
Cheung, Moira S. http://orcid.org/0000-0003-0742-7595
Cobourne, Martyn
Cormier-Daire, Valérie
Deladure-Molla, Muriel
del Pino, Mariana http://orcid.org/0000-0001-6095-7080
Elphick, Heather
Fano, Virginia http://orcid.org/0000-0003-3311-2220
Fauroux, Brigitte
Gibbins, Jonathan
Groves, Mari L.
Hagenäs, Lars http://orcid.org/0000-0002-5605-2462
Hannon, Therese
Hoover-Fong, Julie http://orcid.org/0000-0002-1242-5626
Kaisermann, Morrys http://orcid.org/0000-0002-6495-022X
Leiva-Gea, Antonio http://orcid.org/0000-0002-9286-2796
Llerena, Juan
Mackenzie, William http://orcid.org/0000-0002-6847-1197
Martin, Kenneth
Mazzoleni, Fabio
McDonnell, Sharon
Meazzini, Maria Costanza http://orcid.org/0000-0001-9596-570X
Milerad, Josef
Mohnike, Klaus
Mortier, Geert R. http://orcid.org/0000-0001-9871-4578
Offiah, Amaka http://orcid.org/0000-0001-8991-5036
Ozono, Keiichi http://orcid.org/0000-0002-6517-8825
Phillips, John A. III
Powell, Steven http://orcid.org/0000-0001-7181-4608
Prasad, Yosha
Raggio, Cathleen
Rosselli, Pablo
Rossiter, Judith
Selicorni, Angelo
Sessa, Marco
Theroux, Mary
Thomas, Matthew
Trespedi, Laura
Tunkel, David
Wallis, Colin
Wright, Michael
Yasui, Natsuo
Fredwall, Svein Otto
- License Information
-
More Information
Article History
Accepted: 29 October 2021
First Online: 26 November 2021
Competing interests
: R.S. has received consulting fees and grants from BioMarin and was an investigator in clinical trials for achondroplasia for BioMarin. I.A. has received honorarium from BioMarin and Ascendis Pharma; travel expenses from Ascendis Pharma, Eurordis, Kyowa Kirin and ERN BOND; personal fees from BioMarin and Ascendis Pharma; and non-financial support from Ascendis Pharma, Eurordis, Kyowa Kirin and ERN BOND. W.A.R.B. has received honoraria, consulting fees and travel expenses from BioMarin. M.B. has received consulting fees and grants from BioMarin, Ascendis, Therachon, QED and Alexion, grants from BioMarin, Ascendis, Therachon, QED, Medlife, SOBI and Shire, and was an investigator in BioMarin clinical trials for achondroplasia. J.C. has received personal fees from BioMarin. P.C. has received support from Ascendis and Pfizer for local enrolment in company-led achondroplasia natural history studies. M.C. has received honoraria from BioMarin and is an investigator in achondroplasia trials by BioMarin, Ascendis, QED and Pfizer. M.D.P. has received personal fees and grants from BioMarin. V.F. has received grants and personal fees from BioMarin. M.G. has received honoraria from BioMarin. L.H. has received a grant to Karolinska Institute from BioMarin to work with achondroplasia data and consultant fees from BioMarin, Ascendis and Kyowa Kirin. J.H.F. has received consulting fees from BioMarin, Therachon and Ascendis, grants from BioMarin, and is an investigator in BioMarin clinical trials for achondroplasia. A.L-G. has received honoraria, consulting fees, and travel expenses from BioMarin and was an investigator in BioMarin clinical trials for achondroplasia. M.I. has received consulting fees from BioMarin and was an investigator in BioMarin clinical trials for achondroplasia. J.L. has received grants and personal fees from BioMarin. W.M. has served on advisory boards for LPA, BioMarin, and MPS and has received consulting fees, honoraria and travel expenses from BioMarin. K.M. has served as a BioMarin advisory board member and has received personal fees from BioMarin. K.M. has received consulting fees and grants from BioMarin and was an investigator in BioMarin clinical trials for achondroplasia. G.M. has received honoraria from BioMarin and is involved in the Dreambird study (Therachon/Pfizer) and the Silverbird study (recifercept) for which he receives payments from Pfizer. A.O. has received personal fees, non-financial support, support with manuscript preparation, and travel fees and subsistence for initial expert meetings from BioMarin and served as a reader for imaging in a BioMarin clinical trial for achondroplasia. A.O. has also received grants from Alexion and is involved with the Alexion Research project: Development of dREAMS. K.O. has received honoraria from BioMarin and was an investigator in a BioMarin clinical trial for achondroplasia. J.P. has received fees for board membership and travel from BioMarin. C.R. serves on the advisory board of OIF, EDS, and SDMC and has received consulting fees from BioMarin, Ascendis, Alexion, and Mereo and provided contracted research to BioMarin, Nextcure, and OIF. C.R. is also a member of the speaker’s bureau for BioMarin and Alexion. D.T. has received honoraria and travel expenses from BioMarin relating to his participation on advisory panels in relation to a project seeking to define best practice guidelines for individuals with achondroplasia. N.Y. was an investigator in the BioMarin clinical trial for achondroplasia and has nothing additional to disclose. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
